EU Says Nitrosamine Risk Info Also Needed For New Drug Filings

Incomplete Info May Impact Granting Of Marketing Authorization

Companies seeking approval of new drugs must provide information on nitrosamine-related risk evaluation either as part of their marketing application or during the evaluation process.

Research analyst adding reagent to drug to keep tracking chemical reaction - Image
EU Has Updated Guidance On Nitrosamine Risk Evaluations • Source: Shutterstock

EU regulators have announced that the requirement for companies to undertake nitrosamine-related risk evaluations applies not just to approved medicines, but also to new medicines being submitted for authorization as well as those under review.

Companies are expected to submit this information as well as details of confirmatory testing, where needed, either as part of...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Manufacturing

More from Compliance